WEST BRIDGEWATER, Mass., Sept. 10 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that data highlighting the advantages of pressure cycling technology (PCT) in studies to (1) better understand the events surrounding stroke, (2) detect biomarkers of colon cancer, and (3) detect proteins associated with embryo viability are to be presented this week in three presentations at the 29th Annual Meeting of the British Mass Spectrometry Society (BMSS). The data were generated by scientists at The New York University (NYU) School of Medicine and the Brooklyn Hospital Center. The presentations will be delivered by Dr. Paul Pevsner, M.D. of the NYU School of Medicine.
Approximately three hundred scientists from around the world are expected to attend the BMSS meeting, where mass spectrometry-related data generated in many key areas of human, animal, and plant research will be showcased. The meeting is being held at the Heriot-Watt University in Edinburgh Scotland.
Dr. Paul H. Pevsner, senior author of the research studies and a scientific investigator at the NYU School of Medicine, said: "Our research program is focused in three areas. First, we are investigating the cascade of events that occurs immediately following a stroke, in an effort to develop successful post-stroke therapeutics. Second, we are attempting to discover new biomarkers of colon cancer, in an effort to develop better surgical aids and diagnostics. Third, we are trying to identify proteins associated with embryo viability from growth media fluid, in an effort to develop better in- vitro fertilization techniques."
Dr. Pevsner continued: "In all cases, we were extremely pleased that
PCT could successf
|SOURCE Pressure BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved